Liquidia Corporation reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company generated $148.3 million in product sales, primarily from its newly launched inhalation powder, YUTREPIA, which received FDA approval in May 2025 and began commercialization in June 2025. This marks a substantial increase from the previous year, where no product sales were recorded. However, service revenue from a promotion agreement with Sandoz decreased by 28% to $10 million, attributed to lower sales volumes of Sandoz's generic treprostinil injection.
The company's total revenue for 2025 reached $158.3 million, a significant rise from $14 million in 2024. Despite this growth, Liquidia reported a net loss of $68.9 million, a decrease from a loss of $128.3 million in 2024, indicating improved operational efficiency. The increase in costs was primarily driven by a 93% rise in selling, general, and administrative expenses, which totaled $157.2 million, largely due to increased personnel and commercial expenses associated with the launch of YUTREPIA.
Strategically, Liquidia has made notable advancements, including the development of L606, a liposomal formulation of treprostinil, which is currently undergoing clinical trials. The company has also expanded its manufacturing capabilities, leasing a new facility in Morrisville, North Carolina, to support its growth. As of December 31, 2025, Liquidia employed 216 individuals, reflecting its commitment to scaling operations in response to market demands.
Looking ahead, Liquidia's future financial performance will heavily depend on the continued success of YUTREPIA and the progress of L606 through clinical trials. The company faces ongoing litigation with United Therapeutics, which could impact its ability to maintain FDA approval for YUTREPIA. Despite these challenges, Liquidia believes it has sufficient cash reserves to meet its operational needs for at least the next twelve months, although it may require additional financing to support its growth and development initiatives. The company remains focused on expanding its product pipeline and navigating the competitive landscape of the biopharmaceutical industry.
About Liquidia Corp
Liquidia Corporation is a biopharmaceutical company specializing in developing, manufacturing, and commercializing innovative therapies for rare cardiopulmonary diseases like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Utilizing its proprietary PRINT particle engineering technology, the company creates targeted inhaled and injectable drug formulations, focusing on improving safety, efficacy, and patient convenience through novel delivery systems and strategic partnerships.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.